RATIONALE: Induced pluripotent stem cells (iPSCs) hold great promise for the development of patient-specific therapies for cardiovascular disease. However, clinical translation will require preclinical optimization and validation of large-animal iPSC models. OBJECTIVE: To successfully derive endothelial cells from porcine iPSCs and demonstrate their potential utility for the treatment of myocardial ischemia. METHODS AND RESULTS: Porcine adipose stromal cells were reprogrammed to generate porcine iPSCs (piPSCs). Immunohistochemistry, quantitative PCR, microarray hybridization, and angiogenic assays confirmed that piPSC-derived endothelial cells (piPSC-ECs) shared similar morphological and functional properties as endothelial cells isolated from the autologous pig aorta. To demonstrate their therapeutic potential, piPSC-ECs were transplanted into mice with myocardial infarction. Compared with control, animals transplanted with piPSC-ECs showed significant functional improvement measured by echocardiography (fractional shortening at week 4: 27.2±1.3% versus 22.3±1.1%; P<0.001) and MRI (ejection fraction at week 4: 45.8±1.3% versus 42.3±0.9%; P<0.05). Quantitative protein assays and microfluidic single-cell PCR profiling showed that piPSC-ECs released proangiogenic and antiapoptotic factors in the ischemic microenvironment, which promoted neovascularization and cardiomyocyte survival, respectively. Release of paracrine factors varied significantly among subpopulations of transplanted cells, suggesting that transplantation of specific cell populations may result in greater functional recovery. CONCLUSIONS: In summary, this is the first study to successfully differentiate piPSCs-ECs from piPSCs and demonstrate that transplantation of piPSC-ECs improved cardiac function after myocardial infarction via paracrine activation. Further development of these large animal iPSC models will yield significant insights into their therapeutic potential and accelerate the clinical translation of autologous iPSC-based therapy.
RATIONALE: Induced pluripotent stem cells (iPSCs) hold great promise for the development of patient-specific therapies for cardiovascular disease. However, clinical translation will require preclinical optimization and validation of large-animal iPSC models. OBJECTIVE: To successfully derive endothelial cells from porcine iPSCs and demonstrate their potential utility for the treatment of myocardial ischemia. METHODS AND RESULTS: Porcine adipose stromal cells were reprogrammed to generate porcine iPSCs (piPSCs). Immunohistochemistry, quantitative PCR, microarray hybridization, and angiogenic assays confirmed that piPSC-derived endothelial cells (piPSC-ECs) shared similar morphological and functional properties as endothelial cells isolated from the autologous pig aorta. To demonstrate their therapeutic potential, piPSC-ECs were transplanted into mice with myocardial infarction. Compared with control, animals transplanted with piPSC-ECs showed significant functional improvement measured by echocardiography (fractional shortening at week 4: 27.2±1.3% versus 22.3±1.1%; P<0.001) and MRI (ejection fraction at week 4: 45.8±1.3% versus 42.3±0.9%; P<0.05). Quantitative protein assays and microfluidic single-cell PCR profiling showed that piPSC-ECs released proangiogenic and antiapoptotic factors in the ischemic microenvironment, which promoted neovascularization and cardiomyocyte survival, respectively. Release of paracrine factors varied significantly among subpopulations of transplanted cells, suggesting that transplantation of specific cell populations may result in greater functional recovery. CONCLUSIONS: In summary, this is the first study to successfully differentiate piPSCs-ECs from piPSCs and demonstrate that transplantation of piPSC-ECs improved cardiac function after myocardial infarction via paracrine activation. Further development of these large animal iPSC models will yield significant insights into their therapeutic potential and accelerate the clinical translation of autologous iPSC-based therapy.
Authors: Jeremy I Pearl; Andrew S Lee; Dennis B Leveson-Gower; Ning Sun; Zhumur Ghosh; Feng Lan; Julia Ransohoff; Robert S Negrin; Mark M Davis; Joseph C Wu Journal: Cell Stem Cell Date: 2011-03-04 Impact factor: 24.633
Authors: Franklin D West; Steve L Terlouw; Dae Jin Kwon; Jennifer L Mumaw; Sujoy K Dhara; Kowser Hasneen; John R Dobrinsky; Steven L Stice Journal: Stem Cells Dev Date: 2010-08 Impact factor: 3.272
Authors: Kazim H Narsinh; Ning Sun; Veronica Sanchez-Freire; Andrew S Lee; Patricia Almeida; Shijun Hu; Taha Jan; Kitchener D Wilson; Denise Leong; Jarrett Rosenberg; Mylene Yao; Robert C Robbins; Joseph C Wu Journal: J Clin Invest Date: 2011-02-07 Impact factor: 14.808
Authors: Jiesi Luo; Lingfeng Qin; Mehmet H Kural; Jonas Schwan; Xia Li; Oscar Bartulos; Xiao-Qiang Cong; Yongming Ren; Liqiong Gui; Guangxin Li; Matthew W Ellis; Peining Li; Darrell N Kotton; Alan Dardik; Jordan S Pober; George Tellides; Marsha Rolle; Stuart Campbell; Robert J Hawley; David H Sachs; Laura E Niklason; Yibing Qyang Journal: Biomaterials Date: 2017-09-19 Impact factor: 12.479
Authors: Veronica Sanchez-Freire; Andrew S Lee; Shijun Hu; Oscar J Abilez; Ping Liang; Feng Lan; Bruno C Huber; Sang-Ging Ong; Wan Xing Hong; Mei Huang; Joseph C Wu Journal: J Am Coll Cardiol Date: 2014-08-05 Impact factor: 24.094